Second Phase Trial for Tivic Health ncVNS System

Image credit: Tivic Health and The Feinstein Institutes for Medical Research

Health tech company, Tivic Health has commenced the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation (ncVNS) system.

Working in partnership with The Feinstein Institutes for Medical Research at Northwell Health, a second 20-person clinical trial will be conducted to identify optimal device specifications.

The company said its successful Phase 1 pilot study showed a novel ncVNS approach with potential clinical application for a range of conditions including epilepsy, post-traumatic stress disorder, and ischemic stroke.

“Our recently released ncVNS results demonstrated a large clinically important change in biomarkers for the brain, heart, and autonomic nervous system,” said Tivic Health Chief Scientific Officer, Dr Blake Gurfein in a statement.

“This next phase of the research will build upon those results to tailor the therapy to specific clinical indications and accelerate our product development.”

Refer to the full press release via Tivic Health to learn more.